JP7146732B2 - 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法 - Google Patents
宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法 Download PDFInfo
- Publication number
- JP7146732B2 JP7146732B2 JP2019501578A JP2019501578A JP7146732B2 JP 7146732 B2 JP7146732 B2 JP 7146732B2 JP 2019501578 A JP2019501578 A JP 2019501578A JP 2019501578 A JP2019501578 A JP 2019501578A JP 7146732 B2 JP7146732 B2 JP 7146732B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- apcs
- platform
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 77
- 230000030741 antigen processing and presentation Effects 0.000 title claims description 12
- 230000000259 anti-tumor effect Effects 0.000 title description 16
- 230000036039 immunity Effects 0.000 title description 7
- 230000002223 anti-pathogen Effects 0.000 title 1
- 108091007433 antigens Proteins 0.000 claims description 214
- 102000036639 antigens Human genes 0.000 claims description 214
- 239000000427 antigen Substances 0.000 claims description 211
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 176
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 93
- 206010028980 Neoplasm Diseases 0.000 claims description 91
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 78
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 claims description 78
- 239000002671 adjuvant Substances 0.000 claims description 73
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 59
- 229960000556 fingolimod Drugs 0.000 claims description 57
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 52
- 210000004443 dendritic cell Anatomy 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 48
- 102000004127 Cytokines Human genes 0.000 claims description 36
- 108090000695 Cytokines Proteins 0.000 claims description 36
- 229960005486 vaccine Drugs 0.000 claims description 27
- 230000028993 immune response Effects 0.000 claims description 23
- 241000606161 Chlamydia Species 0.000 claims description 18
- 238000004132 cross linking Methods 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 210000002865 immune cell Anatomy 0.000 claims description 10
- 101150013553 CD40 gene Proteins 0.000 claims description 9
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 9
- 239000012678 infectious agent Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 208000012498 virus associated tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 88
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 76
- 108700014844 flt3 ligand Proteins 0.000 description 71
- 210000001744 T-lymphocyte Anatomy 0.000 description 65
- 108090000765 processed proteins & peptides Proteins 0.000 description 65
- 238000011282 treatment Methods 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 238000001727 in vivo Methods 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 35
- 230000001965 increasing effect Effects 0.000 description 34
- 201000010099 disease Diseases 0.000 description 26
- 230000037452 priming Effects 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 230000005867 T cell response Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 108091008875 B cell receptors Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- -1 1-ethyl Chemical group 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000002648 combination therapy Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 102100032937 CD40 ligand Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 230000002601 intratumoral effect Effects 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 108010029697 CD40 Ligand Proteins 0.000 description 8
- 241000701806 Human papillomavirus Species 0.000 description 8
- 102000002689 Toll-like receptor Human genes 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 229940030156 cell vaccine Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 101710127489 Chlorophyll a-b binding protein of LHCII type 1 Proteins 0.000 description 7
- 101710184917 Chlorophyll a-b binding protein of LHCII type I, chloroplastic Proteins 0.000 description 7
- 239000004971 Cross linker Substances 0.000 description 7
- 101710204615 Eukaryotic translation initiation factor 6 Proteins 0.000 description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 7
- 210000000581 natural killer T-cell Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000006994 Precancerous Conditions Diseases 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 231100000617 superantigen Toxicity 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 229940123189 CD40 agonist Drugs 0.000 description 4
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 4
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 4
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 4
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 description 4
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 108060003552 hemocyanin Proteins 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000003297 immature b lymphocyte Anatomy 0.000 description 3
- 238000011502 immune monitoring Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000003519 mature b lymphocyte Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 description 3
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241001647367 Chlamydia muridarum Species 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241001495184 Chlamydia sp. Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010044394 Hemerythrin Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 101000959746 Homo sapiens Eukaryotic translation initiation factor 6 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000037453 T cell priming Effects 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004520 cell wall skeleton Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 2
- 229960005225 mifamurtide Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- 101150091609 CD274 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 101100335079 Mus musculus Flt3lg gene Proteins 0.000 description 1
- 101100182715 Mus musculus Ly6c2 gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 206010041848 Squamous cell carcinoma of the cervix Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- MYYARUCLXARAEE-ZATZPJRKSA-N alpha-C-GalCer Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCCCCC MYYARUCLXARAEE-ZATZPJRKSA-N 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940029202 anti-idiotypic vaccine Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 201000006824 bubonic plague Diseases 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 102000055691 human APC Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010071932 peptide 946 Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940038237 tumor antigen vaccine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Description
本出願は、2016年7月13日に出願された米国仮出願第62/361,591号、及び2017年1月10日に出願された米国仮出願第62/444,460号の利益を主張するものであり、これらはその全体が参照により本明細書に組み込まれる。
「FTY720」は、「フィンゴリモド」としても知られている。FTY720は、多発性硬化症(MS)を処置するために、臨床的に最も多く使用される、免疫調節薬である。フィンゴリモドは、スフィンゴシン-1-ホスフェート受容体モジュレータであり、これは、リンパ節においてリンパ球を隔離し、リンパ球が自己免疫反応の一因となることを阻止する。同様に、当業者に公知のFTY720のアナログも企図される。
抗原提示細胞(APC)の有効性を増強するための、少なくとも2種のサイトカインを含む組成物を含むプラットフォームであって、サイトカインの2種が、Fms関連チロシンキナーゼ3リガンド(Flt-3L)及び顆粒球-マクロファージコロニー刺激因子(GM-CSF)であり、Flt-3Lが、8μg/kg以下で投与される量で存在し、抗原が負荷されているAPCの集団が、APCを含む内因性免疫細胞に負荷抗原を提示するよう意図されている、プラットフォームが本明細書において開示されている。
対象において、a)対象からAPCを取得することと、b)工程a)に由来するAPCをクラミジア属種又は活性タンパク質、ペプチド若しくはそれらの断片に曝露することと、c)APCを抗CD40モノクローナル抗体に曝露することと、d)APCを所望の抗原に曝露することを含む、活性化された、抗原提示クラミジア活性化抗原提示細胞(APC)を生成する方法であって、抗原がクラミジア属種に由来せず、これにより、活性化抗原提示細胞(クラミジア活性B細胞、すなわちCABなど)を得る方法が、本明細書において開示されている。工程b)、c)及びd)は、任意の順序で行われ得ることが留意される。抗IL6及び抗PDL-1モノクローナル抗体は、この方法に由来するCABと一緒に、それを必要とする対象に投与され得る。
それを必要とする対象において、抗原提示細胞(APC)の有効性を増強するための方法であって、a)対象に、抗IL6及び抗PDL-1モノクローナル抗体を含む組成物を投与することと、b)対象に、抗原及びアジュバントと架橋されている又はこれらが負荷されたAPCの集団を投与することと、を含む方法が本明細書において開示されている。抗体は、それを必要とする対象に同時に投与することができるか、又は一方が、もう一方の前に投与されてもよい。例えば、それらは、互いに、1、2、3、4、5、6又はそれより長い時間、離して投与することができる。
本明細書において開示されている抗原提示細胞(APC)は、さまざまな出所源に由来することができる。例には、以下に限定されないが、クラミジア活性化B細胞(CAB)、CD40活性化B細胞、樹状細胞などのB細胞、及びナノ粒子、抗DEC-205抗体コンジュゲート及び抗CLEC9抗体コンジュゲートなどの人工APC(細胞由来又は合成)が含まれる。
プラットフォームによる使用のための、本明細書において開示されている抗原は、任意のタンパク質、ペプチド、全不活性化生物、又は任意のアミン含有分子とすることができる。多数の疾患、障害又は状態に起因する関連抗原を使用してもよい。例示的な抗原としては、以下に限定されないが、細菌、ウイルス、寄生虫、アレルゲン、自己抗原及び腫瘍関連抗原が挙げられる。DNA又はRNAに基づくワクチンが使用される場合、抗原は、典型的に、投与されたDNA又はRNA構築物の配列によってコードされる。代替的に、抗原が、コンジュゲートとして投与される場合、この抗原は、典型的に、投与された共役体に含まれるタンパク質となろう。本明細書に開示されるAPCは、同時に又は逐次的に、1つを超える抗原に、曝露又は架橋することができる。例えば、本明細書において開示されるAPCは、同時に又は逐次的に、2種、3種、4種、5種、6種若しくはそれ超の抗原に曝露することができるか、又は異なる単一抗原を負荷したAPCを、投与のために一緒に組み合わせることができる。
本明細書に記載されている方法及び組成物により、幅広いアジュバントが使用され得る。例となるアジュバントには、以下に限定されないが、無機塩、サポニン、多糖類、脂質、リポポリサッカライド(内毒素)、核酸又はタンパク質が挙げられる。
上記のとおり、本明細書に記載されているプラットフォームは、他の因子も含むことができる。これらの因子には、以下に限定されないが、1-エチル1-3-(3-ジメチルアミノプロピル)-カルボジイミド(EDAC)、シクロヘキシミド(CHX)及びα-ガラクトシルセラミド(α-GalCer)、又は等価物が含まれる。EDAC、CHX及びα-GalCer(又は他の等価アジュバントであり、以下に議論されている)を、FTY720、Flt-3L及び/又はGM-CSFを含むプラットフォームと一緒に、又は個別に使用することができる。
GM-CSF及びFlt-3Lは、個別に、又は互いに組み合わせて投与することができる。例えば、GM-CSFは、2μg/kg以下で投与される量で存在することができる。投与されるGM-CSFの量は、患者に特異的な、さまざまな因子に基づいて決定することができる。GM-CSFは、0.5~2.0μg/kg、又はそれ未満の範囲で投与することができる。したがって、投与される量は、2.0、1.9、1.8、1.7、1.6、1.5、1.4、1.3、1.2、1.1、1.0、0.9、0.8、0.7、0.6、0.5、0.4、0.3、0.2若しくは0.1μg/kg、又は上記未満の任意の量、上記より多い任意の量、又はこれらの間の量とすることができる。
さまざまな培養培地のうちのいずれかが、当業者に知られている方法で使用され得る(例えば、Current Protocols in Cell Culture,2000~2009 by John Wiley & Sons,Inc.を参照されたい)。一実施形態では、本明細書に記載の方法で使用するための培地としては、改変ダルベッコ培地(ウシ胎児又は他の適切な血清を含む、若しくは含まない)が挙げられるが、これに限定されない。例示的な培地としては、IMDM、RPMI 1640、AIM-V、DMEM、MEM、a-MEM、F-12、X-Vivo 15及びX-Vivo 20も挙げられるが、これらに限定されない。更なる実施形態では、培地は、界面活性剤、抗体、プラスマネート若しくは還元剤(例えば、N-アセチル-システイン、2-メルカプトエタノール)、又は1種若しくは複数の抗生物質を含み得る。一部の実施形態では、IL-2、IL-4、IL-6、IL-10、アゴニスト抗CD40モノクローナル抗体、可溶性CD40L及び架橋増強剤、又は照射済みtCD40L NIH/3T3細胞も使用することができる。B細胞は、所望の活性化を達成するための条件下で、所望の活性化を達成するのに十分な期間培養され得る。ある種の実施形態では、B細胞は、B細胞の10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、又は更には100%の活性化が所望される条件下で、それに十分な期間培養される。
非常に高用量の腫瘍細胞(4×105個)が投与される、非常に侵襲性の高いモデル(すなわち、B16-F10黒色腫)を使用すると、CAB治療法と抗PDL-1 mAbとの間の明瞭な相乗性が確認された(とりわけ、抗PD-1を代替として使用することができた)。興味深いことに、図27及び28に示されているとおり、抗IL-6をこの併用療法に加えると、抗腫瘍活性の顕著な増大が検出された(抗IL-6の添加により処置された群では、腫瘍量の低下及び生存率の向上によって実証される)。これらの検討の場合、腫瘍注射後の8日目に開始して、合計7回の用量分の抗PDL-1 mAbを、1日おき(すなわち、最初の5回の用量分のCAB治療法と同時に)に、単独で、又は抗IL-6 mAbと組み合わせて投与した。抗IL-6 mAbの添加により、併用療法によって誘発される腫瘍特異的CD8+ T細胞応答の向上に影響を及ぼすことなく、CAB及び抗PDL-1併用療法によって引き起こされる、有害な炎症応答を低減することができるように思われる。抗PDL1 mAbと抗IL-6 mAbとの組合せは、腫瘍処置に一層早期に使用された場合、CAB治療法を使用しない場合でさえも、相乗効果を有することができる。
この実施例は、図20に図示されている実験系を使用しており、この場合、オボアルブミン及びα-GCを負荷したCABを点滴する1日前に、蛍光標識されている、オボアルブミン特異的TCRトランスジェニックCD8+ T細胞を、未感作C57BL/6マウスに導入した。示されているとおり、これらのマウスはまた、FTY720又は小胞により処置した。図21に示されているデータは、FTY720を投与すると、CAB治療法の、抗原特異的CD8+ T細胞の増殖をインビボで活性化して誘発する能力が著しく向上することを実証している。更に、図22及び23に示されているとおり、単回用量のCAB治療法にFTY720を添加すると、このHPV関連腫瘍のマウスモデルにおいて、腫瘍の完全な排除をもたらした。
免疫磁気陰性選択によって単球を欠失させたヒト末梢血単核球細胞を、合計で8日間、ヒト組換えIL-2及び抗CD40アゴニストmAbの存在下で、不活性化したC.トラコマチス血清型L2 RBに曝露させる。この系を使用すると、この抗体の不在下で増殖した細胞に比べて、クラミジアと、クラミジア活性化B細胞を生成するための抗CD40アゴニストmAbとの間に明確な相乗作用があることが分かった(図29)。
EG.7-OVA腫瘍のマウスモデルにおいて、マウスに、約120万個のEG.7-OVA細胞を皮下注射した。この処置の7、8及び9日後に、マウスに低用量のGM-CSF及びFlt-3Lを投与した。3回目のGM-CSF/Flt-3L処置後の当日に、マウスにOVAを負荷した活性化B細胞を投与した。未処置対照では、腫瘍サイズは着実に増大したが、GM-CSF及びFlt-3Lにより処置したマウスでは、腫瘍サイズは低下する(これらのマウスの40%において、腫瘍は検出不可能になった)ことが分かった。反対に、腫瘍成長は、腫瘍投与後のGM-CSF/Flt-3L単独で処置したマウスでは制御されなかった。
Claims (17)
- 抗原提示の有効性及び抗原特異的免疫応答を増強するためのプラットフォームであって、
前記プラットフォームが、
a.対象に投与される、少なくとも2種のサイトカインを含む組成物であって、前記2種のサイトカインがFlt-3L及びGM-CSFであり、Flt-3Lが8μg/kg以下で前記対象に投与される量で存在する、組成物と、
b.前記対象に投与される、抗原が負荷された抗原提示細胞(APC)の集団と、
を含み、
前記aの前記組成物は、前記bの前記抗原が負荷されたAPCの前記集団の前記対象への投与前に前記対象に投与される、プラットフォーム。 - 前記bの前記APCは、アジュバントと架橋されているか又はアジュバントが負荷されている、請求項1に記載のプラットフォーム。
- 前記抗原が負荷されたAPCの前記集団が、内因性免疫細胞に前記負荷された抗原を提示する、請求項1に記載のプラットフォーム。
- 前記APCが、クラミジア属種に暴露して活性化させたB細胞であるクラミジア活性化B細胞(CAB)である、請求項1に記載のプラットフォーム。
- 前記APCがCD40活性化B細胞である、請求項1に記載のプラットフォーム。
- 前記APCが樹状細胞である、請求項1に記載のプラットフォーム。
- 前記APCが人工APCである、請求項1に記載のプラットフォーム。
- 請求項1に記載のプラットフォームを製造する方法であって、
前記対象に投与される、少なくとも2種のサイトカインを含む組成物であって、前記2種のサイトカインがFlt-3L及びGM-CSFであり、Flt-3Lが8μg/kg以下で前記対象に投与される量で存在する、組成物と、
抗原提示細胞(APC)をシクロヘキシミド(CHX)により処理した後に抗原と架橋して得た、前記対象に投与される、前記抗原が負荷された抗原提示細胞(APC)の集団と、
を含む、プラットフォームを製造する工程を有する、
方法。 - 前記APCが、α-ガラクトシルセラミド(α-GalCer)又はα-C-GC、C18、C22、C23、7DW8-5、7DW8-6、α-GC C24:0若しくはα-Carba-GCに曝露されている、請求項1に記載のプラットフォーム。
- 前記APCが、FTY720又はFTY720のアナログに曝露されている、請求項1に記載のプラットフォーム。
- 前記プラットフォームが、1種超の抗原を含む、請求項1に記載のプラットフォーム。
- 前記抗原が、腫瘍関連抗原又はウイルス関連腫瘍抗原を含む、請求項1に記載のプラットフォーム。
- 前記抗原が、感染性因子の1つ以上の構成成分を含む、請求項1に記載のプラットフォーム。
- GM-CSFが、2μg/kg以下で前記対象に投与される量で存在する、請求項1に記載のプラットフォーム。
- FTY720が、50μg/kg以下で前記対象に投与される量で存在する、請求項10に記載のプラットフォーム。
- ワクチンを作製するための、請求項1に記載のプラットフォーム。
- ワクチンを作製するための、請求項10に記載のプラットフォーム。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361591P | 2016-07-13 | 2016-07-13 | |
US62/361,591 | 2016-07-13 | ||
US201762444460P | 2017-01-10 | 2017-01-10 | |
US62/444,460 | 2017-01-10 | ||
PCT/US2017/041948 WO2018013820A1 (en) | 2016-07-13 | 2017-07-13 | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019524728A JP2019524728A (ja) | 2019-09-05 |
JP2019524728A5 JP2019524728A5 (ja) | 2020-08-13 |
JP7146732B2 true JP7146732B2 (ja) | 2022-10-04 |
Family
ID=60951914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019501578A Active JP7146732B2 (ja) | 2016-07-13 | 2017-07-13 | 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11850279B2 (ja) |
EP (1) | EP3485002A4 (ja) |
JP (1) | JP7146732B2 (ja) |
CN (1) | CN109563481B (ja) |
AU (1) | AU2017294751B2 (ja) |
CA (1) | CA3030779A1 (ja) |
WO (1) | WO2018013820A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008527051A (ja) | 2006-04-27 | 2008-07-24 | ソウル ナショナル ユニバーシティー インダストリー ファウンデーション | ナチュラルキラーt細胞のリガンドと抗原を積載したb細胞を媒介とするワクチン |
JP2011036258A (ja) | 1998-12-08 | 2011-02-24 | Corixa Corp | クラミジア感染の処置および診断のための化合物および方法 |
WO2013118899A1 (ja) | 2012-02-10 | 2013-08-15 | 医療法人社団博心厚生会 | 単球増殖剤、単球増殖用培地、単球の製造方法、樹状細胞の製造方法、及び樹状細胞ワクチンの製造方法 |
WO2013132526A1 (en) | 2012-03-07 | 2013-09-12 | Istituto Superiore Di Sanita' | Use of sphingosine-1 -phosphate receptors modulators for improving vaccine immunization |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579945A (en) | 1982-04-29 | 1986-04-01 | Ribi Immunochem Research, Inc. | Purification of trehalose dimycolates |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
CZ307995A3 (en) | 1993-05-24 | 1996-10-16 | Immunex Corp | Ligands for flt3 receptors |
US20020034517A1 (en) * | 1995-10-04 | 2002-03-21 | Kenneth Brasel | Dendritic cell stimulatory factor |
US7150992B1 (en) | 1995-10-04 | 2006-12-19 | Innunex Corporation | Methods of preparing dendritic cells with flt3-ligand and antigen |
CN1172718C (zh) | 1995-10-04 | 2004-10-27 | 依默耐克斯有限公司 | 树突状细胞刺激因子 |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CA2216559A1 (en) | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
PT1224264E (pt) | 1999-10-15 | 2010-03-15 | Baylor Res Inst | Modificação de células imunogénicas |
JP2004520823A (ja) | 2000-12-13 | 2004-07-15 | イミュネックス・コーポレーション | 不死樹状細胞系の作製方法 |
WO2003009812A2 (en) | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
WO2003051907A2 (en) * | 2001-12-18 | 2003-06-26 | Health Research, Inc. | Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells |
KR100555211B1 (ko) | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Her-2/neu DNA 백신 |
DE10326187A1 (de) * | 2003-06-06 | 2005-01-05 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Zellen als Träger für Bakterien |
GB0314682D0 (en) * | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
US20070048254A1 (en) | 2005-08-24 | 2007-03-01 | Mirus Bio Corporation | Generation of dendritic cells |
US8003093B2 (en) * | 2006-04-27 | 2011-08-23 | Seoul National University Industry Foundation | B cell-based vaccine loaded with the ligand of natural killer T cell and antigen |
GB0911042D0 (en) | 2009-06-25 | 2009-08-12 | Istituto Superiore Di Sanito | Treatment of tumorigenic cells in solid tumours |
US10105435B2 (en) * | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
WO2013158819A2 (en) | 2012-04-20 | 2013-10-24 | St. Jude Children's Research Hospital | Method for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential |
JP2016531907A (ja) | 2013-08-02 | 2016-10-13 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. | 免疫刺激のためのcd27アゴニストと免疫チェックポイント阻害との組み合わせ |
CN107206258A (zh) * | 2015-02-10 | 2017-09-26 | 俄亥俄州创新基金会 | 衣原体激活的b细胞平台及其方法 |
CA3004924A1 (en) * | 2015-11-10 | 2017-05-18 | Ohio State Innovation Foundation | Methods and compositions related to accelerated humoral affinity |
-
2017
- 2017-07-13 JP JP2019501578A patent/JP7146732B2/ja active Active
- 2017-07-13 US US16/317,247 patent/US11850279B2/en active Active
- 2017-07-13 CN CN201780049510.XA patent/CN109563481B/zh active Active
- 2017-07-13 EP EP17828469.1A patent/EP3485002A4/en active Pending
- 2017-07-13 CA CA3030779A patent/CA3030779A1/en active Pending
- 2017-07-13 AU AU2017294751A patent/AU2017294751B2/en active Active
- 2017-07-13 WO PCT/US2017/041948 patent/WO2018013820A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011036258A (ja) | 1998-12-08 | 2011-02-24 | Corixa Corp | クラミジア感染の処置および診断のための化合物および方法 |
JP2008527051A (ja) | 2006-04-27 | 2008-07-24 | ソウル ナショナル ユニバーシティー インダストリー ファウンデーション | ナチュラルキラーt細胞のリガンドと抗原を積載したb細胞を媒介とするワクチン |
WO2013118899A1 (ja) | 2012-02-10 | 2013-08-15 | 医療法人社団博心厚生会 | 単球増殖剤、単球増殖用培地、単球の製造方法、樹状細胞の製造方法、及び樹状細胞ワクチンの製造方法 |
WO2013132526A1 (en) | 2012-03-07 | 2013-09-12 | Istituto Superiore Di Sanita' | Use of sphingosine-1 -phosphate receptors modulators for improving vaccine immunization |
Non-Patent Citations (2)
Title |
---|
CD40-activated B cells induce anti-tumor immunity in vivo,Oncotarget,2016年02月25日,Vol. 8,p. 27740-27753,https://doi.org/10.18632/oncotarget.7720 |
Flt3 Ligands Induces Monocyte Proliferation and Enhances the Function of Monocyte-Derived Dendritic Cells In Vitro,Journal of Cellular Physiology,2015年,Vol. 230,p. 1740-1749,DOI: 10.1002/jcp.24824 |
Also Published As
Publication number | Publication date |
---|---|
CA3030779A1 (en) | 2018-01-18 |
JP2019524728A (ja) | 2019-09-05 |
CN109563481A (zh) | 2019-04-02 |
EP3485002A4 (en) | 2020-07-29 |
AU2017294751B2 (en) | 2023-10-05 |
AU2017294751A1 (en) | 2019-01-31 |
EP3485002A1 (en) | 2019-05-22 |
US20190224298A1 (en) | 2019-07-25 |
WO2018013820A1 (en) | 2018-01-18 |
CN109563481B (zh) | 2024-01-05 |
US11850279B2 (en) | 2023-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6134763B2 (ja) | GM−CSF及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
US20210340215A1 (en) | T cell receptor constructs and uses thereof | |
US20120269860A1 (en) | Method for Proliferation of Antigen-Specific T Cells | |
RU2565542C2 (ru) | Улучшенная композиция для ингибирования пролиферации опухолевых клеток | |
JP2024019229A (ja) | 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法 | |
Zapala et al. | Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application | |
AU2016219379A1 (en) | Chlamydia-activated B cell platforms and methods thereof | |
Zhao et al. | Dendritic cell transfer for cancer immunotherapy | |
JP7146732B2 (ja) | 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法 | |
JP2023539056A (ja) | T細胞を製造する組成物および方法 | |
JP2022552200A (ja) | 樹状細胞およびT細胞の活性化を増強するためのならびにTH-1免疫応答を誘導するためのin vitroの方法および組成物 | |
Soler et al. | Triiodothyronine-stimulated dendritic cell vaccination boosts antitumor immunity against murine colon cancer | |
US10716810B2 (en) | Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes | |
JP2020505050A (ja) | 免疫寛容性プラズマサイトイド樹状細胞及びその製造方法 | |
Jin et al. | Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines? | |
Zhang | Tolerogenic CD4⁻ 8⁻ Dendritic Cells and their Conversion into Immunogenic Ones via TLR9 Signaling | |
Šımová et al. | Therapy for minimal residual tumor disease: b-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200702 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220921 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7146732 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |